FRACTYL HEALTH, INC.
No SEC Form 4 filings for $GUTS in the last 30 days.
See all $GUTS insider activity →Fractyl Health (GUTS) stock rose 2.8% in pre-market trading ahead of its Virtual Commercial Strategy Day, where management will discuss the commercial strategy for Revita, its procedural therapy. Recent clinical data showed patients maintained 84% of GLP-1-induced weight loss. Analysts from Bank of America and Morgan Stanley have differing ratings. The move is driven by company-specific catalysts, not broader market trends.
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy/top-pick view on Fractyl Health (GUTS), citing progress in its Revita program. He expects pivotal data and a potential De Novo submission in Q4 2026. The article notes Q2 2026 EPS of -$0.16 and cash of $47.1M, and cites an $8 price target.
FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablation
Over the past 7 days, alphai's AI scored 2 news stories mentioning GUTS (FRACTYL HEALTH, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent GUTS coverage spans technology, insider activity and market movers.
The pre‑market price jump reflects trader reaction to the upcoming investor event and recent positive trial data.
The note reinforces a near-term catalyst window (Q4 2026 pivotal readout and potential De Novo submission) and supports the existing risk framework for GUTS.
The filing reinforces the probability-weighted path to a potential FDA De Novo submission in late Q4 2026, supporting risk-on positioning in the near-term catalyst window.
Fractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.
Durable post-GLP-1 weight maintenance results improve the probability of a De Novo path and can re-rate the clinical-stage obesity procedural platform.
alphai scores every news story that mentions GUTS with an AI model for sentiment and relevance, and aggregates insider trades from FRACTYL HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Fractyl Health (GUTS) stock rose 2.8% in pre-market trading ahead of its Virtual Commercial Strategy Day, where management will discuss the commercial strategy for Revita, its procedural therapy. Recent clinical data showed patients maintained 84% of GLP-1-induced weight loss. Analysts from Bank of America and Morgan Stanley have differing ratings. The move is driven by company-specific catalysts, not broader market trends.
2 min readH.C. Wainwright analyst Joseph Pantginis reiterated a Buy/top-pick view on Fractyl Health (GUTS), citing progress in its Revita program. He expects pivotal data and a potential De Novo submission in Q4 2026. The article notes Q2 2026 EPS of -$0.16 and cash of $47.1M, and cites an $8 price target.
4 min readFRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablation
6 min readFractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.
3 min readFractyl Health (GUTS) reported one-year randomized REMAIN-1 midpoint cohort results for its Revita duodenal mucosal resurfacing system in patients who stopped GLP-1 therapy. In 45 participants, Revita cut weight regain versus sham (7.8% vs 13.0% of body weight). Responder rates were 73% vs sham, rising to 91% with complete ablation. Stock rose to $0.80.
5 min readFractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.
5 min readRoyan Ajay purchased 23,000 shares of FRACTYL HEALTH, INC. (GUTS) at $0.85 on 2026-06-12.
2 min readFRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001572616 false 0001572616 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readBRADLEY WILLIAM purchased 68,493 shares of FRACTYL HEALTH, INC. (GUTS) at $0.73 on 2026-06-10.
1 min readSheffield Ian purchased 35,000 shares of FRACTYL HEALTH, INC. (GUTS) at $0.73 on 2026-06-10.
1 min read
